ATTO insider trading
NasdaqGM HealthcareAttovia Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Company website: www.attovia.com
ATTO insider activity at a glance
FilingIQ tracks 123 insider transactions for ATTO in filings since Aug 6, 2026. The most recent transaction is dated Aug 6, 2026.
Across the full history, 13 open-market purchases
and 92 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ATTO insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ATTO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ATTO
Frequently asked
- How many insider trades does FilingIQ track for ATTO?
- FilingIQ tracks 123 Form 4 insider transactions for ATTO (Attovia Therapeutics, Inc.), covering filings from Aug 6, 2026 onwards. 123 of those are dated within the last 90 days.
- Are ATTO insiders net buyers or net sellers?
- Across the full Form 4 history for ATTO, 13 transactions (11%) were open-market purchases and 92 (75%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ATTO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ATTO in?
- Attovia Therapeutics, Inc. (ATTO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.04B.
Methodology & sources
Every ATTO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.